Endo Health Solutions (Nasdaq: ENDP) reported earnings on May 7. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Endo Health Solutions missed estimates on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue increased slightly. Non-GAAP earnings per share expanded significantly. GAAP earnings per share expanded.

Margins increased across the board.

Revenue details
 Endo Health Solutions booked revenue of $708.5 million. The 18 analysts polled by S&P Capital IQ anticipated sales of $741.3 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $1.09. The 18 earnings estimates compiled by S&P Capital IQ predicted $1.08 per share. Non-GAAP EPS of $1.09 for Q1 were 25% higher than the prior-year quarter's $0.87 per share. GAAP EPS were $0.14 for Q1 against -$0.75 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 59.6%, much better than the prior-year quarter. Operating margin was 20.4%, much better than the prior-year quarter. Net margin was 2.2%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $751.0 million. On the bottom line, the average EPS estimate is $1.22.

Next year's average estimate for revenue is $2.90 billion. The average EPS estimate is $4.49.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 417 members out of 439 rating the stock outperform, and 22 members rating it underperform. Among 137 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 131 give Endo Health Solutions a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Health Solutions is outperform, with an average price target of $32.53.